Name: UMIN ID:
Unique ID issued by UMIN | UMIN000008793 |
---|---|
Receipt number | R000010332 |
Scientific Title | Phase II study of remission induction therapy with bendamustine and rituximab combination (BR) therapy followed by consolidation therapy with 90Y-labeled iburitumomab tiuxetan for relapsed follicular lymphoma.(BRiZ2012 protocol) |
Date of disclosure of the study information | 2012/09/03 |
Last modified on | 2019/03/04 09:44:53 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2012/08/28 19:50:54 | ||
2 | Update | 2013/07/16 18:01:17 | Recruitment status |
|
3 | Update | 2013/09/02 12:00:29 | Email Institutions |
|
4 | Update | 2014/09/02 14:27:21 | Interventions/Control_1 Interventions/Control_1 Key inclusion criteria Key inclusion criteria |
|
5 | Update | 2014/09/02 14:37:22 | Institute Institutions |
|
6 | Update | 2014/09/02 14:38:51 | Last follow-up date |
|
7 | Update | 2016/05/06 09:19:19 | Recruitment status |
|
8 | Update | 2016/09/01 09:27:03 | Name of primary person or sponsor Organization Institutions |
|
9 | Update | 2019/03/04 09:44:53 | Recruitment status Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded Publication of results Results Other related information |